|Title of Invention||
PHARMACEUTICAL DERMAL COMPOSITION USEFUL IN TREATMENT OF DIABETIC COMPLICATIONS
|Abstract||The present invention provides methods of treating diabetic complications, the methods comprising administering to a patient having or at risk of having diabetic complications, a therapeutically effective amount of a Beta adrenergic receptor antagonist or Beta-blockers. This invention is directed to methods, pharmaceutical composition and kits comprising a Beta adrenergic receptor antagonist, prodrug thereof or a pharmaceutically acceptable salt of the said Beta adrenergic receptor antagonists. This invention further relates to pharmaceutical compositions of beta adrenergic antagonists for the treatment of diabetic complications such as diabetic cataract, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic cardiomyopathy, diabetic corneal keraopathy, diabetic dermopathy, diabetic microangiopathy and diabetic wounds.|
|Full Text||FORM 2
THE PATENTS ACT. 1970
(39 of 1970)
The Patents Rules, 2003
Provisional / Complete Specification (See section 10 and Rule 13)
1. Title of the invention : Pharmaceutical composition useful in treatment of
(a) Name : VLife Sciences Technologies Pvt. Ltd.
(b) Nationality: Indian
(c) Address : 1 Akshay Residency, 50 Anand Park, Aundh, Pune 411007, India
3. Preamble to the description: Inhibitors of aldose reductase are reported which would be highly useful in several diseases including diabetes and diabetic complications.
/ The following specification
describes the invention
Complete The following specification particularly describes the invention and the manner in which to be performed
4. Description (Descriptional shall start from next page)
5. Claims (Not applicable for provisional specification. Claims should start with the
preamble 'I/We claim' on separate page)
6. Date & signature (To be given at the end of last page of specification)
7. Abstract of the invention (To be given along with complete specification on separate page)
Title: PHARMACEUTICAL COMPOSITION USEFUL IN THE TREATMENT OF DIABETIC COMPLICATIONS
Name of Inventors: Sudhir A. Kulkarni, Reena Gollapudy, Supreet K. Deshpande (VLife Sciences Technologies Pvt. Ltd., Pride Purple Coronet, S.No. 287, Baner Road, Pune-411045, India)
Assignee: VLife Sciences Technologies Pvt. Ltd., 1 Akshay Residency, 50 Anand Park, Aundh, Pune-411007, India
In spite of the significant development in the antidiabetic therapy, the complications like neuropathy, retinopathy, nephropathy, various angiopathies and cataract continue to be the major causes of morbidity and mortality in diabetic patients. Patients with all forms of diabetes are vulnerable to these complications especially when high blood sugar levels are not adequately controlled. Complications like retinopathy are so characteristic of diabetes that its presence has been incorporated into the nosologic definition of NIDDM ( non insulin dependent diabetes mellitus). Only hyperglycemia of sufficient magnitude to be associated with retinopathy is classified as NIDDM, while lower levels of hyperglycemia that are not accompanied by retinopathy are classified as mere 'impaired glucose tolerance'. There seem to be different pathogenic mechanisms responsible for the diabetic complications. However excessive formation and accumulation of sorbitol in various tissues is believed to play a major role in the development of debilitating diabetic complications. The enzyme aldose reductase converts excess glucose in to sorbitol using NADPH as a co-factor. Hence much effort has been directed towards the synthesis of aldose reductase inhibitors. Aldose reductase inhibitors hold promise for reducing metabolic nerve injury.
A large number of aldose reductase inhibitors have been assessed for diabetic complications, but the lack of consistent efficacy and adverse effects have prevented their widespread use. The search for efficacious, safe and specific inhibitors of aldose reductase enzyme remains a major pharmaceutical challenge.
The present invention describes the beta adrenergic antagonist drugs (beta blockers) as having potent aldose reductase inhibitory activity. Beta adrenergic antagonists with aldose reductase inhibition activity are therefore useful in the prevention and treatment of various diabetic complications including retinopathy. They are also useful in the treatment of wounds and ocular conditions. Atenolol, Nadolol, Timolol, Metipranolol, Propranolol, Metoprolol, Carteolol, Bisoprolol, Sotalol, Celiprolol, Betaxolol, Levobunolol, Carvedilol, Nebivolol, Arotinolol, Labetalol, and Acebutolol are some of the examples of beta adrenergic antagonist drugs. Therapeutically effective amounts of these drugs could be administered by multiple routes-oral, parenteral, intraocular, subconjunctival and topical with appropriate vehicles.
Present disclosure is premised on the reasoning and the fact that the inhibition of aldose reductase by beta blockers helps in prevention and treatment of diabetic complications, the use of the current compounds based on their aldose reductase inhibiting property is not restricted to the diabetic syndrome.
|Indian Patent Application Number||1960/MUM/2006|
|PG Journal Number||45/2011|
|Date of Filing||29-Jan-2007|
|Name of Patentee||VLIFE SCIENCES TECHNOLOGIES PVT. LTD.|
|Applicant Address||1 AKSHAY RESIDENCY, 50 ANANDPARK, AUNDH, PUNE 411007,|
|PCT International Classification Number||A61K31/00|
|PCT International Application Number||N/A|
|PCT International Filing date|